Menu
Share this

PPD In The News

A rare journey: Managing the regulatory landscape

Jonca Bull discusses the significant regulatory actions that have occurred in the rare disease space.

PharmaVOICE  (October 2017)

Bending the Cost and Time Curve of Drug Development through the Use of Biomarkers

In this article written by Katie Matys and Janine McKnight, the authors discuss how the right biomarker can make all the difference in a drug-development program.

Genetic Engineering & Biotechnology News   (October 2017)

How Interested Is The FDA In Real-World Evidence?

Radek Wasiak of Evidera comments on real-world evidence in part three of this three-part series.

Clinical Leader  (September 2017)

Real-World Evidence & The 21st Century Cures Act — What You Need To Know

Radek Wasiak of Evidera comments on real-world evidence in part two of this three-part series.

Clinical Leader  (September 2017)

Functional Service Partnerships: A Case Study for CRO Resource Management

In this article written by Denise Moody, Tim King and Ranjit Bains, the authors review an FSP in which PPD reduced a client’s annual operational spend by assuming responsibility for clinical monitoring and site support.

Pharmaceutical Executive  (September 2017)

Why You Should Care About Real-World Evidence (A Lot)

Radek Wasiak of Evidera comments on real-world evidence in part one of this three-part series.

Clinical Leader  (September 2017)

Dr. Susan Atkinson: Practical Innovator

Read about Susan Atkinson, Ph.D., senior vice president of global biometrics, who was named to the 2017 PharmaVOICE 100 list of the most inspiring people in the life sciences industry.

PharmaVOICE  (August 2017)

Standard data, extraordinary innovations in clinical trials

Tammy Jackson discusses the innovative application of CDISC SDTM standards in clinical trials.

CenterWatch Monthly  (July 2017)

An overview of major reforms in China’s regulatory environment

Alistair Davidson and Bill Wang analyze the potential impact of a series of regulatory changes and improvements on clinical development in China.

Regulatory Rapporteur  (July 2017)

Parallelism experiments: pros and cons

Jing Tu and Patrick Bennett discuss available approaches that can be used to assess key assay parameters for pharmacokinetic and biomarker ligand-binding assays.

Bioanalysis  (July 2017)

Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2017 Pharmaceutical Product Development, LLC. All rights reserved.